Segments

Operating segments are identified as components of an enterprise about which separate discrete financial information is available for evaluation by the CODM or decision-making group in making decisions on how to allocate resources and assess performance. The Company’s CODM is its CEO. The CEO views the Company’s operations and manages the Company’s business as one operating segment, which is the business of developing and commercializing genome editing technology.

The Company’s CEO manages and allocates resources to the operations of the Company on a total company basis by assessing the overall level of resources available and how to best deploy these resources across functions and research and development projects that are in line with our long-term company-wide strategic goals. In making these decisions, the Company’s CEO uses consolidated financial information for purposes of evaluating performance, forecasting future period financial results, allocating resources and setting incentive targets. The CODM performs this assessment based on the Company’s consolidated net loss. Through this analysis, the CODM assesses performance by comparing actual

consolidated net loss versus the budget, and then decides how to allocate resources to invest in the Company’s research and development programs. The measure of segment assets is reported on the consolidated balance sheet as total assets.

The following table contains additional information on our consolidated revenue and net loss, including significant segment expenses (in thousands):


	Year Ended December 31,
	2024		2023		2022
Collaboration and other research and development revenues	$	32,314	$	78,123	$	19,712
Operating expenses:
Research and development1
Employee related expenses	61,136		47,363		47,320
External research and development expenses	79,900		53,321		79,822
Facility expenses	26,430		21,447		21,032
Stock-based compensation expenses	8,642		9,842		12,425
Sublicense and license fees	18,953		35,011		5,334
Other expenses3	12,768		10,667		9,025
General and administrative2
Employee related expenses	24,335		16,969		17,321
Professional service expenses	14,358		19,575		11,496
Intellectual property and patent related fees	14,016		13,268		14,784
Stock-based compensation expenses	12,775		9,956		16,869
Facility and other expenses4	10,153		9,885		10,234
Total operating expenses	283,466		247,304		245,662
Operating loss	(251,152)		(169,181)		(225,950)
Other income, net:
Other expense, net	(3)		(1,604)		—
Interest income, net	14,062		17,566		5,518
Total other income, net	14,059		15,962		5,518
Net loss	$	(237,093)	$	(153,219)	$	(220,432)

1 For the years ended December 31, 2024, 2023, and 2022 includes $8,582, $0, and $0 of restructuring charges, respectively
2 For the years ended December 31, 2024, 2023, and 2022 includes $3,650, $0, and $0 of restructuring charges, respectively
3 Other expenses primarily consists of consultant fees and office expenses
4 Facility and other expenses primarily consists of rent expense, insurance premiums, software licenses and office expenses

For the year ended December 31, 2024, there were two customers for which revenues amount to 10% or more of the Company’s consolidated collaboration and other research and development revenues, representing $18.1 million and $10.0 million of the Company’s consolidated collaboration and other research and development revenues. For the year ended December 31, 2023, there was one customer for which revenues amounts to 10% or more of the Company’s consolidated collaboration and other research and development revenues, representing $60.0 million of the Company’s consolidated collaboration and other research and development revenues. For the years ended December 31, 2024 and 2023, 100% and 100%, respectively, of the Company’s consolidated collaboration and other research and development revenues was attributed to the U.S.

About Segments Disclosures

Segment disclosures break a company into its reportable operating units, revealing revenue, profit, and asset allocation that consolidated financial statements obscure. Under ASC 280, segments must match how the chief operating decision maker views the business, providing a window into internal management structure and resource allocation priorities.

Key signals: compare segment margins to identify which units drive profitability and which destroy value. Watch for changes in the number of reportable segments — segment aggregation or disaggregation often coincides with strategic shifts or attempts to obscure declining performance. Intersegment elimination patterns reveal internal pricing practices. The reconciliation between segment totals and consolidated figures exposes corporate overhead allocation and unallocated items. Geographic revenue concentration highlights regulatory and currency exposure. Compare segment-level capital expenditure against segment revenue to assess where management is investing for future growth versus harvesting existing assets.

Editas Medicine, Inc. Segments Disclosure

About Segments Disclosures

Other Available Disclosures